Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 8.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 8.5 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Ariad Pharmaceuticals, Inc., Astellas, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Celgene Corporation, Genentech, Lilly, Merck Sharp & Dohme Corp., Novartis, and Pfizer.

For further information concerning Lilly grant funding visit

11th Annual New York Lung Cancer Symposium®

11th Annual New York Lung Cancer Symposium®

November 12, 2016
Crowne Plaza® Times Square Manhattan
New York, NY


The 11th Annual New York Lung Cancer Symposium® is a 1-day educational and scientific meeting that will provide an update on state-of-the-art management of patients with lung cancer, as well as a focus on future therapies in development.

The past decade in lung cancer research has yielded a wealth of therapeutic options for patients with lung cancer, as well as greater knowledge of the many different subtypes of this disease. In particular, agents targeting oncogenic drivers and immunotherapeutic approaches have both transformed the management of patients with lung cancer in recent years. Furthermore, numerous investigational approaches are in late-phase evaluation, with the potential to change standards of care in 2016 and beyond. However, although these developments hold the promise to further improve outcomes for patients with lung cancer, they also raise challenges for busy clinicians to maintain state-of-the-art approaches in their practices.

This year’s program, led by world-class thoracic oncologists Mark G. Kris, MD, and Roman Perez-Soler, MD, will focus on a number of core areas that are key to optimizing care for patients with lung cancer, including targeted therapy, immunotherapy, adjuvant therapy, combined modality therapy, and approaches for challenging subtypes, such as squamous lung cancer. Participants will have an opportunity to learn from engaging presentations delivered by leading experts, as well as apply their knowledge in case-based panel discussions. This fast-paced, highly practical, and interactive forum will once again provide physicians who treat patients with lung cancer unique access to renowned international experts in the management of these tumors.

Target Audience

This educational activity is directed toward medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists involved in the treatment and management of patients with lung cancer.  Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of lung cancer may also participate.

Program Chairs

Mark G. Kris, MD
Attending, Thoracic Oncology Service
William and Joy Ruane Chair in Thoracic Oncology
Memorial Sloan Kettering Cancer Center
New York, NY

Roman Perez-Soler, MD
Chairman, Department of Oncology
Montefiore Medical Center
Professor of Medicine and Molecular Pharmacology
Deputy Cancer Center Director
Albert Einstein College of Medicine
Bronx, NY


You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information

Registration Information

In case of onsite emergency:

Professional Information


Calendar of Events
Filter By